First-in-human clinical trial of the small-diameter (3.5mm) acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG)
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Human acellular vessel-Humacyte (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; First in man
- 28 Jan 2025 New trial record
- 21 Jan 2025 According to Humacyte media release, the company plans to file an Investigational New Drug (IND) application with the USFDA to allow first-in-human clinical testing of the small-diameter (3.5mm) acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG), based on the outcome of a recent meeting held with the FDA, including agreements reached with the agency.